Articles related to DEVICE/DRUG APPROVALS

64% of those who self-administered Cardamyst converted to sinus rhythm within 30 minutes compared with 31% who received placebo.

“People are more used to taking pills than they are taking injections” but “90% of a person’s weight is the result of what they eat. There are no magic solutions.”

“The updated label for Nexplanon reflects the diversity of patients we see every day, women throughout their reproductive ages, those seeking a long-acting option of up to 5 years, those who prefer birth control that goes in the arm rather than the uterus, and women across a wide range of BMIs,” said Anita Nelson, MD, Professor, Obstetrics and Gynecology at Western University of Health Sciences.

“We are surprised and disappointed by this FDA decision for EBV+ PTLD patients who have a significant unmet need, highlighted by tabelecleucel’s orphan drug designation and by the granting of breakthrough status.” — Dr. Cokey Nguyen, Atara CEO

“Menopause does not mark the end of a woman’s sexuality but for too long, medicine has treated it that way.”

Linzess is the first treatment approved for IBS-C in pediatric patients. Patients younger than 2 years can be at risk of serious dehydration and should not take Linzess for any indication.